CRSP vs. BEAM
Compare and contrast key facts about CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CRSP or BEAM.
Key characteristics
| CRSP | BEAM | |
|---|---|---|
| YTD Return | -10.72% | -15.03% |
| 1Y Return | 5.21% | -30.48% |
| 3Y Return (Ann) | -21.57% | -31.78% |
| Sharpe Ratio | 0.23 | -0.37 |
| Daily Std Dev | 58.94% | 71.96% |
| Max Drawdown | -81.61% | -86.76% |
| Current Drawdown | -73.39% | -82.69% |
Fundamentals
| CRSP | BEAM | |
|---|---|---|
| Market Cap | $4.74B | $1.90B |
| EPS | -$1.94 | -$1.72 |
| Revenue (TTM) | $371.21M | $377.71M |
| Gross Profit (TTM) | -$570.70M | -$250.67M |
| EBITDA (TTM) | -$202.70M | -$156.47M |
Correlation
The correlation between CRSP and BEAM is 0.68, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
CRSP vs. BEAM - Performance Comparison
In the year-to-date period, CRSP achieves a -10.72% return, which is significantly higher than BEAM's -15.03% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
CRSP vs. BEAM - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
CRSP vs. BEAM - Dividend Comparison
Neither CRSP nor BEAM has paid dividends to shareholders.
Drawdowns
CRSP vs. BEAM - Drawdown Comparison
The maximum CRSP drawdown since its inception was -81.61%, smaller than the maximum BEAM drawdown of -86.76%. Use the drawdown chart below to compare losses from any high point for CRSP and BEAM. For additional features, visit the drawdowns tool.
Volatility
CRSP vs. BEAM - Volatility Comparison
The current volatility for CRISPR Therapeutics AG (CRSP) is 11.69%, while Beam Therapeutics Inc. (BEAM) has a volatility of 15.00%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
CRSP vs. BEAM - Financials Comparison
This section allows you to compare key financial metrics between CRISPR Therapeutics AG and Beam Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities